Celexa/Lexapro MDL winds up
Celexa/Lexapro MDL winds up

Introduction
The U.S. District Judge Nathaniel M. Gorton granted Forest Laboratories’ motion for summary judgment on all claims made by the plaintiffs who alleged that the company fraudulently promoted Celexa and Lexapro for pediatric depression. This ruling brings an end to the long-running Massachusetts MDL 2067: In Re: Celexa and Lexapro Marketing and Sales Practices Litigation.
Comments
Latest News
First Federal Bellwether Trial Set in Strattice Mesh Case
Categories: Hernia Mesh
Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…
Tepezza Hearing Loss Trial Set for June 2026
Categories: Tepezza
The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.
This decision comes as attorneys…